Brepocitinib clears or almost clears skin in 69% of patients with cutaneous sarcoidosis in Phase 2 BEACON trial – Priovant
Priovant Therapeutics has published results from the Phase 2 portion of the BEACON study of oral brepocitinib in adults with cutaneous sarcoidosis (CS) in JAMA Dermatology. Dr Misha… read more.
